LCA 0321
Alternative Names: LCA-0321Latest Information Update: 31 Mar 2025
At a glance
- Originator Lycia Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Thyroid-stimulating immunoglobulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Graves ophthalmopathy; Graves' disease
Most Recent Events
- 11 Feb 2025 Preclinical trials in Graves ophthalmopathy in USA (unspecified route) prior to February 2025 (Lycia Therapeutics Pipeline, February 2025)
- 11 Feb 2025 Preclinical trials in Graves' disease in USA (unspecified route) prior to February 2025 (Lycia Therapeutics Pipeline, February 2025)
- 11 Feb 2025 Pharmacodynamics data from a preclinical study in Graves’ disease released by Lycia Therapeutics, prior to February 2025 (Lycia Therapeutics Pipeline, February 2025)